Neurographics

Neuroimaging of Substance Abuse

M.A. Naveed, P. Feizi, and R.I. Mehta

View Article on Neurographics Website

Date of Activity Release: Feb. 1, 2019
Date of Activity Expiration: Feb. 1, 2022

Target Audience:
Intended for neuroradiologists and neuroradiology trainees with varying degrees of experience.

Learning Objective:
To become familiar with the mechanism of action, pathophysiology, neuropathology, and neuroimaging features of commonly used drugs.

Abstract
Substance use disorder is one of the most critical current public health crises in the United States and is the cause of morbidity and mortality of many Americans. Neuroimaging plays an important role in diagnosing and assessing prognosis of patients who have this disorder. Drugs of abuse target the brain reward system, which plays a central role in addiction. Substance use may cause reversible or irreversible neurologic injuries, disability, and death through various mechanisms. This article reviews the neurotoxic effects and neuroimaging manifestations of various commonly used drugs to aid physicians in diagnosis, management, and prediction of outcome of patients with this disorder.

Commercial Support
No commercial support was received for this activity.

Credit Designation Statement

The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Neuroradiology designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician Participation:
Each participant will review the corresponding Neurographics article located at www.neurographics.org. Upon completion, each physician will complete and pass a post-test with a score of at least 80% to receive a CME certificate.

Disclosures:
All individuals in control of content have disclosed the following relevant financial relationships. All of these relationships were treated as a conflict of interest, and have been resolved (C7 SCS 6.1-6.2, 6.5)

Authors:
Authors have no relevant financial relationships.

Planners:

Name

Role

Relationship/Interest

Barton Branstetter 

Editor in Chief

None, N/A

Adam Flanders

Deputy Editor

Royalties, Lippincott Williams and Wilkins

Robert Quencer 

Consulting Editor

None, N/A

Mark Mullins

Associate Editor

Non-remunerative position, AUR6

Meng Law

Associate Editor

Stockholder, Clinical Imaging

Edward Escott

Associate Editor

Grant, Atherysys, Inc.; Royalties, Thieme Medical Publishers

Scott Faro

Associate Editor

None, N/A

Tina Young Poussaint

Associate Editor

None, N/A

Dheeraj Ghandi

Associate Editor

Grant, Arstasis, Axera Inc.; Consultant, Covidien, EV3

Contact Information:
If you have questions regarding this enduring material activity, please contact us at ngstaff@asnr.org.

Privacy Policy and Confidentiality Policy:
The ASNR does not share your personal information provided to this site with any third party, except where required by CME governing bodies for verification of CME activities. Your email address will only be used to contact you in relation to your activities on the website, except where you have given ASNR permission to contact you with additional information. ASNR adheres to the same policy for members as nonmembers, except that: ASNR member mailing address information may be shared with providers of accredited CME activities.


Copyright © American Society of Neuroradiology, 2011-2019